This is a France news story, published by Gizmodo, that relates primarily to Ozempic news.
For more France news, you can click here:
more France newsFor more Ozempic news, you can click here:
more Ozempic newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Gizmodo, you can click here:
more news from GizmodoOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
weight loss medications Ozempic. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest semaglutide news, novel hydrogel version news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
insulinGizmodo
•
83% Informative
Scientists in France have unveiled a novel hydrogel version of semaglutide, the active ingredient in the diabetes and weight loss medications Ozempic and Wegovy.
The slow-releasing version should allow people to only need a monthly injection of these drugs, rather than once-a-week as currently required.
VR Score
80
Informative language
78
Neutral language
64
Article tone
semi-formal
Language
English
Language complexity
59
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
3
Source diversity
3
Affiliate links
no affiliate links